Matsuoka Hideaki, Fujimura Takao, Hayashi Masako, Matsuda Kaori, Ishii Yoshinori, Aramori Ichiro, Mutoh Seitaro
Pharmacology Research Laboratories, Astellas Pharma Inc., 2-1-6 Kashima, Osaka 532-8514, Japan.
Biochem Pharmacol. 2007 Aug 1;74(3):465-76. doi: 10.1016/j.bcp.2007.05.002. Epub 2007 May 6.
Previous studies have shown that HDAC inhibitors selectively inhibit IL-2 gene expression, but the mechanism of this inhibition remains to be elucidated. It was recently reported that HDAC4, a component of the nuclear hormone receptor corepressor (N-CoR) complex, associates with the IL-2 promoter via the transcription factor myocyte enhancer factor 2 (MEF2). We therefore focused on the role of HDAC4/N-CoR complex in the transcriptional regulation of IL-2. Four approaches were used to characterize this role and to investigate the relation between the regulatory function of HDAC4/N-CoR complex and HDAC4-enzymatic activity: (i) HDAC4 silencing by RNA interference, (ii) overexpression of N-CoR repression domain 3 (RD3), (iii) overexpression of HDAC4 point mutants, and (iv) treatment with HDAC inhibitors. Here, we report that HDAC4 plays an essential role in IL-2 promoter activation, and that the formation of the HDAC4/N-CoR complex, which is closely related to HDAC4-enzymatic activity, might be involved in HDAC inhibitor-mediated inhibition of IL-2 gene expression. These observations indicate that the selective inhibition of HDAC4 or the interaction of HDAC4 with N-CoR is likely a potential target for the development of novel immunosuppressants.
先前的研究表明,组蛋白去乙酰化酶(HDAC)抑制剂可选择性抑制白细胞介素-2(IL-2)基因的表达,但其抑制机制仍有待阐明。最近有报道称,核激素受体共抑制因子(N-CoR)复合物的组成成分HDAC4通过转录因子肌细胞增强因子2(MEF2)与IL-2启动子相关联。因此,我们重点研究了HDAC4/N-CoR复合物在IL-2转录调控中的作用。我们采用了四种方法来表征这一作用,并研究HDAC4/N-CoR复合物的调控功能与HDAC4酶活性之间的关系:(i)通过RNA干扰使HDAC4沉默;(ii)过表达N-CoR抑制结构域3(RD3);(iii)过表达HDAC4点突变体;(iv)用HDAC抑制剂进行处理。在此,我们报告HDAC4在IL-2启动子激活中起关键作用,并且与HDAC4酶活性密切相关的HDAC4/N-CoR复合物的形成可能参与了HDAC抑制剂介导的对IL-2基因表达的抑制。这些观察结果表明,选择性抑制HDAC4或HDAC4与N-CoR的相互作用可能是开发新型免疫抑制剂的潜在靶点。